CNS Pharmaceutical

CNS Pharmaceuticals is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. CNS may also pursue the development of Berubicin to treat additional diseases, including pancreatic and ovarian cancers and lymphoma. CNS may also develop combination therapies that include Berubicin.

CNS Pharmaceutical headquartered in United States, North America, operates in the Biotechnology, Life Science, Pharmaceutical, Therapeutics sector. The company focuses on Biotechnology and has secured $1.5B in funding across 64 round(s). With a team of 1-10 employees, CNS Pharmaceutical is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - CNS Pharmaceutical, raised $1.4M. Discover more about their projects, partnerships, and impact on our platform.